# Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

> **NCT00677365** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 151 (actual)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** MP-376
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00677365
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677365, "Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00677365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*